Publication

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

Related publications (50)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

Graph Chatbot

Chat with Graph Search

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia